Radient Technologies Inc.

RTI.H

CA75034P1062

Pharmaceuticals

Delayed Toronto S.E. Other stock markets 03:56:03 2023-03-07 pm EST			5-day change	1st Jan Change
0.005 ^CAD	-.--%		-.--%	-.--%

2023	Radient Technologies Inc. Announces the Resignation of Interim Chairman Jocelyne Lafreniere from its Board of Directors	CI
2023	Radient Technologies Inc. announced that it has received CAD 0.4 million in funding	CI

Radient Technologies Inc. Reaffirms Financial Guidance for the Third Quarter Ended December 31, 2019

January 14, 2020 at 07:30 am EST

Radient Technologies Inc. reaffirmed financial guidance for the third quarter ended December 31, 2019. the company expected to meet or exceed its previously disclosed revenue target of at least CAD 10 million for its Third Quarter 2020 fiscal quarter ended December 31, 2019.

Latest news about Radient Technologies Inc.

Radient Technologies Inc. Announces the Resignation of Interim Chairman Jocelyne Lafreniere from its Board of Directors	23-05-17	CI
Radient Technologies Inc. announced that it has received CAD 0.4 million in funding	23-04-19	CI
Radient Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-29	CI
Radient Technologies Inc. Appoints Steven Splinter as Interim CEO	22-10-28	CI
Radient Technologies Inc. Appoints Dimitris Tzanis as Director	22-10-28	CI
Radient Technologies Inc. announced that it expects to receive CAD 1.2 million in funding	22-10-27	CI
Radient Technologies Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-10-21	CI
Radient Technologies Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	22-09-30	CI
Radient Technologies Inc. Auditor Raises 'Going Concern' Doubt	22-09-29	CI
Radient Technologies Inc. Announces Board Changes	22-09-01	CI
Radient Technologies Inc. cancelled the acquisition of PBR Laboratories Inc.	22-08-14	CI
Radient Technologies Inc. announced that it expects to receive CAD 1.2 million in funding	22-06-16	CI
Radient Technologies Inc. Amends Loan Facility as Part of Restructuring Plan	22-04-04	CI
Radient Technologies Inc. announced that it expects to receive CAD 9.93 million in funding from Moskowitz Capital Mortgage Fund II Inc.	22-04-03	CI
Radient Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-28	CI
Radient Technologies Inc. completed the acquisition of Tunaaaa Room Xtracts Inc. for $8.075 million.	22-01-27	CI
Radient Announces Partnership with All Good for Cannabis Pre-Roll Production and Provides Shareholder Update	22-01-05	CI
Radient Technologies Inc. announced that it has received CAD 1.252843 million in funding	21-12-30	CI
Radient Technologies Inc. announced that it expects to receive CAD 1.2 million in funding	21-12-14	CI
Radient Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-29	CI
Radient Technologies Inc. Reports Earnings Results for the Full Year Ended March 31, 2021	21-10-01	CI
Radient Technologies Inc. Auditor Raises 'Going Concern' Doubt	21-09-30	CI
Radient Technologies Inc. Announces Submission of Application to Health Canada for Additional Sales Licenses	21-08-09	CI
Radient Technologies Inc. entered into a letter of intent to acquire PBR Laboratories Inc. for CAD 0.77 million.	21-07-28	CI
Radient Technologies Inc.(TSXV:RTI) dropped from S&P/TSX Venture Composite Index	21-07-19	CI

Chart Radient Technologies Inc.

Duration

Period

More charts

Company Profile

Radient Technologies Inc. is a science-based company. The Company is a commercial manufacturer of cannabinoid-based formulations, ingredients, and products. The principal activities of the Company and its subsidiaries are engaged in research, development, and commercialization of an efficient and environmentally responsible technology for the extraction, isolation, and purification of soluble products from a range of materials using microwave technology and a customized hydrocarbon extraction platform. The Company is focused on the formulation, manufacturing and launching of value-added cannabis products. It utilizes a proprietary extraction and downstream processing platform that recovers up to 99% of cannabinoids from the cannabis plant. It develops specialty products and ingredients that contain a range of cannabinoid and terpene profiles.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
RADIENT TECHNOLOGIES INC.	-.--%	1.98M
DONG-E-E-JIAO CO.,LTD.	+43.31%	6.29B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-16.99%	4.42B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+6.39%	3.3B
TASLY PHARMACEUTICAL GROUP CO., LTD	-13.10%	3.05B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-4.17%	2.47B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+45.47%	1.94B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-9.11%	1.66B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-2.09%	1.61B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.50%	1.54B

Alternative Medicine